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Abstract
Background: Neurotrophins and their receptors regulate several aspects of the developing and mature nervous
system, including neuronal morphology and survival. Neurotrophin receptors are active in signaling endosomes, which
are organelles that propagate neurotrophin signaling along neuronal processes. Defects in the Npc1 gene are
associated with the accumulation of cholesterol and lipids in late endosomes and lysosomes, leading to
neurodegeneration and Niemann-Pick type C (NPC) disease. The aim of this work was to assess whether the endosomal
and lysosomal alterations observed in NPC disease disrupt neurotrophin signaling. As models, we used i) NPC1-deficient
mice to evaluate the central cholinergic septo-hippocampal pathway and its response to nerve growth factor (NGF)
after axotomy and ii) PC12 cells treated with U18666A, a pharmacological cellular model of NPC, stimulated with NGF.
Results: NPC1-deficient cholinergic cells respond to NGF after axotomy and exhibit increased levels of choline
acetyl transferase (ChAT), whose gene is under the control of NGF signaling, compared to wild type cholinergic
neurons. This finding was correlated with increased ChAT and phosphorylated Akt in basal forebrain homogenates.
In addition, we found that cholinergic neurons from NPC1-deficient mice had disrupted neuronal morphology,
suggesting early signs of neurodegeneration. Consistently, PC12 cells treated with U18666A presented a clear NPC
cellular phenotype with a prominent endocytic dysfunction that includes an increased size of TrkA-containing
endosomes and reduced recycling of the receptor. This result correlates with increased sensitivity to NGF, and, in
particular, with up-regulation of the Akt and PLC-g signaling pathways, increased neurite extension, increased
phosphorylation of tau protein and cell death when PC12 cells are differentiated and treated with U18666A.
Conclusions: Our results suggest that the NPC cellular phenotype causes neuronal dysfunction through the
abnormal up-regulation of survival pathways, which causes the perturbation of signaling cascades and anomalous
phosphorylation of the cytoskeleton.
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Background
Neurotrophins (NGF, BDNF, NT3 and NT4) regulate
different aspects of the developing and mature nervous
system, including neuronal survival and neuronal mor-
phology. These small proteins exert these effects by
binding to members of the Trk family of receptor tyro-
sine kinases (TrkA, TrkB and TrkC) or to the p75 neu-
rotrophin receptor (p75). Whereas p75 binds all
neurotrophins, in addition to other ligands (e.g., pro-
neurotrophins and amyloid peptides), each Trk binds
preferentially to its cognate neurotrophin. For example,
TrkA, TrkB and TrkC bind NGF, BDNF and NT3,
respectively [1-3].
Several neurodegenerative diseases are produced by
alterations in molecules related to endocytosis and
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vesicular trafficking, which are cellular processes that
regulate neurotrophin signaling [4,5]. Therefore, one
possible target of endosomal abnormalities and traffick-
ing defects is neurotrophin signaling [6,7].
Niemann-Pick type C (NPC) disease is a fatal autoso-
mal recessive disorder resulting from mutations in the
NPC1 (in 95% of patients) or the NPC2 gene (in 5% of
patients). The loss of NPC1 or NPC2 function causes
the accumulation of cholesterol and glycosphingolipids
in the late endocytic pathway. Some evidence has sug-
gested that the accumulation of cholesterol and other
lipids inside the cell results in endosomal abnormalities,
including alterations in the recycling pathway and
alterations in late endosome dynamics, in addition to
the down-regulation of neurotrophic signaling [8-17].
Although most mammalian cells are affected by intracel-
lular cholesterol overload, neurodegeneration is the
main cause of fatality in patients with NPC disease
[8,10].
NPC disease shares several similarities, including late
endosomal and lysosomal abnormalities, neurofibrillary
tangles and cognitive impairment, with other neurode-
generative disorders, such as Alzheimer’s disease (AD)
[18,19]. A typical NPC patient will develop cerebellar
ataxia and progressive cognitive deterioration, in addi-
tion to compromised organ function [8,11,20]. In AD,
cognitive impairment is correlated with neurodegenera-
tion of the central cholinergic system. Basal forebrain
cholinergic neurons account for most of the cholinergic
innervation of the hippocampus and cortical mantle and
play a key role in the regulation of synaptic activity and
the modulation of memory and attention [21-24].
Derangement of the cholinergic system is one of the
pathological hallmarks of AD and contributes to the
progressive cognitive deterioration of AD patients [25].
NPC patients also show cognitive decline [20], but no
study has examined the possible causes underlying the
neuropathological alterations associated with cognitive
impairment in this disease [26,27].
The aim of this work was to assess whether the endo-
somal alterations that are observed in mouse and cellu-
lar models of NPC disease disrupt NGF signaling. We
used two different models: NPC1-deficient (NPC1-/-)
mice and PC12 cells treated with U18666A (PC12-
U18666A cells), a well-known inducer of the NPC phe-
notype [28-31]. Contrary to our expectations, NGF sig-
naling was up-regulated or conserved in both models of
NPC, suggesting that neurodegeneration in NPC may
result from the misregulation of kinase cascades trig-
gered by neurotrophins as well as other trophic factors.
Methods
Goat polyclonal anti-ChAT antibody was obtained from
Chemicon (Temecula, CA, USA). Rabbit polyclonal
anti-p75, mouse monoclonal anti-PLCg and rabbit poly-
clonal anti-TrkA antibodies were obtained from Upstate
Biotech (Charlottesville, USA). Mouse monoclonal anti-
tau (AT8) and mouse monoclonal anti-Flag antibodies
were obtained from Pierce (Rockford, Illinois, USA).
Mouse monoclonal anti-neurofilament antibody was
obtained from Sigma (St. Louis, Missouri, USA). Bioti-
nylated secondary antibodies against rabbit and mouse
IgG and protease-free serum bovine albumin (BSA)
were obtained from Jackson ImmunoResearch (West
Grove, Pennsylvania, USA). The following were
obtained from Molecular Probes (Invitrogen, Maryland,
USA): mouse monoclonal antibody against Alexa Fluor
488; Alexa Fluor 488 carboxylic acid, 2,3,5,6-tetrafluoro-
phenyl ester (Alexa Fluor 488 5-TFP); transferrin conju-
gated to Alexa Fluor 568; phalloidin Alexa Fluor 546;
LysoTracker Red DND-99; Alexa Fluor 488-conjugated
donkey anti-rabbit antibody; Alexa Fluor 594-conjugated
donkey anti-goat antibody; Alexa Fluor 488-conjugated
donkey anti-mouse antibody; and Alexa Fluor 555-con-
jugated cholera toxin subunit-B (CT-B). NGF was
obtained from Alamone Labs (Jerusalem, Israel). ALZET
Osmotic pumps (model 1002) were obtained from Alza
Corp. (Palo Alto, California, USA). The ABComplex-
peroxidase kit and 3-’3-diaminobenzidine were obtained
from DakoCytomation (California, USA). Mowiol and
phosphatase inhibitor cocktail were obtained from Cal-
biochem (San Diego, California, USA). Wortmannin was
obtained from Sigma-Aldrich (St. Louis, USA).
U18666A was obtained from Biomol (Plymouth Meet-
ing, Pennsylvania, USA). Phospho-PLC-g rabbit polyclo-
nal, phospho-ERK1/2 rabbit polyclonal, ERK1/2 rabbit
polyclonal and Akt rabbit polyclonal antibodies were
obtained from Cell Signaling (Beverly, Massachusetts,
USA). Phospho-Akt rabbit polyclonal antibody was
obtained from Santa Cruz Biotechnology (Santa Cruz,
California, USA). The protease inhibitor cocktail was
obtained from Roche (Hertfordshire, UK). All other
reagents were obtained from Sigma (St. Louis, Missouri,
USA). The plasmid for Rab7-GFP was a gift from Ceci-
lia Bucci (University of Salento, Lecce, Italy). The plas-
mid for Rab5-GFP was a gift from Victor Faundez
(Emory University, USA). The plasmid for TrkA-Flag
was a gift from Francis Lee (Cornell University, NY,
USA).
Animals
BALB/c mice carrying a heterozygous mutation in the
Npc1 gene were kindly donated by Dr. Peter Pentchev
(U.S. National Institutes of Health, Bethesda, MD, USA).
The genotypes were determined by polymerase chain
reaction (PCR)-based screening as described previously
[32]. All animal protocols were approved by the Animal
Studies Review Board of our institution.
Cabeza et al. Molecular Neurodegeneration 2012, 7:11
http://www.molecularneurodegeneration.com/content/7/1/11
Page 2 of 18
Mice were anesthetized with a mixture of xylazine (12
mg/kg) and ketamine (80 mg/kg) administered i.p., and
9% lidocaine was applied locally to the ears. Mice were
then positioned in a stereotaxic apparatus, and coordi-
nates were calculated based on the Franklin and Paxinos
atlas of the mouse brain [33]. After surgery, the animals
were injected i.p. with the antibiotics ketoprofen (2.5
mg/kg) and enrofloxacin (5 mg/kg) for four days and
maintained under observation and temperature control
for one week. For histological preparation of brain tis-
sue, anesthetized mice were transcardially perfused with
40 ml of 0.9% NaCl and 20 ml of 4% paraformaldehyde
(PFA) in phosphate buffer. After extraction, the brain
was post-fixed overnight in 4% PFA, left in 30% sucrose
for 24 hrs, and coronally sectioned (40 μm) on a
cryostat.
Fimbria-fornix transection and intracerebroventricular
infusion of NGF
Unilateral axotomy of the septo-hippocampal pathway
was induced by aspirative lesion of the fimbria-fornix as
previously described [34]. In brief, anesthetized mice
were positioned in a stereotaxic apparatus, and a small
piece of skull was removed at the stereotaxic coordi-
nates 0.6 mm caudal to the bregma and 0.0-2.0 mm lat-
eral to the midline. After excision of the dura, we
performed a syringe aspiration of the dorsal fornix-fim-
bria with a 5-ml syringe fitted with a 25 G 5/8” needle.
We also used the syringe to aspirate part of the cingu-
late and parietal cortices. Mice were sacrificed 7 days
after axotomy.
Artificial cerebrospinal fluid (ACSF; 150 mM NaCl,
1.8 mM CaCl2, 1.2 mM MgSO4, 2 mM KH2PO4 and 10
mM glucose, pH 7.4) with or without 20 μg/ml NGF
(100 μl per osmotic pump) was infused for 7 days with
a brain infusion kit (Alza Corp.) connected to a model
1002 ALZET osmotic pump, as described previously
[34]. The cannulae and connector tubes were filled with
ACSF or ACSF plus NGF and attached to a filled pump.
Using the arm of the stereotaxic apparatus, each cannula
was lowered into the brain at the coordinates of the left
ventricle (0.2 mm caudal to bregma, 0.8 mm to the mid-
line of the contralateral side and 1.8 mm ventral to the
brain surface). The cannula was anchored to the skull
with a screw and glued with dental acrylic. Axotomized
mice were infused with NGF for 7 days immediately fol-
lowing axotomy.
AChE enzyme histochemistry
Serial coronal cryostat sections (40 μm) were collected
in 0.1 M phosphate buffer (pH 7.4), washed in 65 mM
sodium maleate (pH 6.0) and incubated as floating sec-
tions for staining for 1 hr at room temperature (RT) in
a solution containing 0.05 mg/mL acetylthiocholine
iodide, 0.1 mM tetra-isopropyl-pyrophosphatamide, 0.05
mM potassium ferricyanide, 0.3 mM CuSO4, 0.5 mM
sodium citrate and 65 mM sodium maleate (pH 6.0), as
described previously [35].
Immunohistochemistry of brain sections
Immunohistochemistry was performed as follows: (i) 15
min incubation in 0.03% H2O2 in 0.1 M Tris-HCl, and
150 mM NaCl, pH 7.4 (TBS) to block endogenous per-
oxidase; (ii) 30 min incubation at 4°C in 0.4% Triton X-
100 in TBS; (iii) 1.5 hr incubation at 4°C in 0.2% Triton
X-100, 5% fetal calf serum (FCS) and 5% BSA in TBS;
(iv) 24 hr incubation at 4°C with primary antibody in
TBS plus 0.2% Triton-X100 and 5% FCS; (v) 1.5 hr incu-
bation at RT with biotin-conjugated secondary antibody;
and (vi) 1 hr incubation with peroxidase-conjugated avi-
din ABC (DakoCytomation), followed by visualization of
peroxidase activity with diaminobenzidine (DAB, 1 mg/
mL) and 0.01% H2O2 in TBS. Primary antibodies were
used at the following dilutions: anti-ChAT (1:300), anti-
p75 (1:500) and anti-neurofilament (1:2000). Sections
were immediately rinsed in distilled water, mounted, air-
dried, cleared with xylene and mounted in Entellan.
Immunofluorescence of brain sections
Single or double immunofluorescence was performed in
floating brain sections as follows: (i) 15 min incubation
in TBS; (ii) 15 min incubation in 0.15 M glycine in TBS;
(iii) 15 min incubation in TBS; (iv) 10 min incubation in
NaBH4 (10 mg/ml) in TBS; (iii) 30 min incubation at 4°
C in 0.3% Triton X-100 in TBS; (iv) 1.5 hr incubation at
4°C with 0.2% Triton X-100, 5% FCS, and 2% BSA in
TBS; (v) 15 min incubation in TBS; (vi) 24 hr incubation
at 4°C with primary antibodies in 0.2% Triton X-100, 5%
FCS and 2% BSA in TBS; (vii) 15 min incubation in
TBS; and (vii) 1.5 hr incubation at RT with fluoro-
chrome-conjugated 2% BSA in TBS. Sections were
immediately rinsed in distilled water and mounted in
Mowiol.
NeuroTrace (fluorescent Nissl stain; Molecular
Probes) staining was performed by incubating brain sec-
tions for 20 min in a 1:200 dilution of NeuroTrace in
TBS. Fluoro-Jade C (a specific marker for degenerating
neurons; Chemicon) staining was performed after Neu-
roTrace as follows. Brain sections were rinsed twice in
TBS, re-hydrated for 2 min in distilled water and incu-
bated for 10 min in 0.06% potassium permanganate.
Finally, brain sections were washed for 2 min in distilled
water and incubated for 10 min in 0.0002% Fluoro-Jade
C solution in 0.1% acetic acid. Sections were immedi-
ately rinsed in distilled water, mounted, air dehydrated,
cleared with xylene and mounted in Entellan.
Cholesterol staining with filipin, a polyene macrolide
that binds to free cholesterol, was performed in brain
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sections that were previously labeled for ChAT by
immunohistochemistry [36]. Sections were incubated
with filipin (50 μg/mL) in TBS for 2 hrs at RT in the
dark. Sections were then washed in TBS for 15 min and
mounted in Mowiol.
The cholinergic cell count was performed as described
previously [35]. Septal cholinergic neurons were defined
using anatomical landmarks in accordance with the
mouse brain atlas [33]. The anterior commissure and
anterior and lateral ventricles defined the ventral border
of the medial septum (MS). The meeting of the body of
the corpus callosum at the midline marked the anterior
boundary of the MS, and the midline crossing of the
anterior commissure and the appearance of the fornix
marked the posterior boundary. Four 40-μm-thick coro-
nal sections per mouse were taken through the complete
MS with a 160-μm interval between each section to
avoid counting the same cells twice (coordinates from
BREGMA: 1.10 to 0.5 mm). ChAT-immunopositive cells
were counted on images digitized with an Olympus
BX51 (Tokyo, Japan) microscope. The criterion for iden-
tifying ChAT-immunopositive cells was the appearance
of a clear nuclear shape or, in cases when staining was
too dark, clear neuronal morphology.
Cell culture
PC12 cells were grown in DMEM containing L-gluta-
mine and high glucose and supplemented with 6% horse
serum, 6% fetal calf serum and 100 U/ml penicillin-
streptomycin. For differentiation assays, PC12 cells were
seeded at a density of 10-15,000 cells per square centi-
meter on poly-D-lysine-coated 16-mm coverslips and
maintained for 24, 48 or 72 hrs in the presence of NGF
(5 ng/ml) in DMEM/glutamine/high glucose supplemen-
ted with 1 mg/ml BSA. Cells were considered differen-
tiated when they had at least one neurite that was twice
the diameter of the cell body.
To reproduce the cellular phenotype of NPC disease,
PC12 cells were treated with different concentrations
(0.5-2 mg/ml) of the drug U18666A, which causes the
accumulation of cholesterol in the late endosomes and
lysosomes [31].
For filipin staining of PC12 cells, cells were fixed for
10 min with cold paraformaldehyde (4%) in PBS, rinsed
twice with cold PBS, incubated for 10 min in glycine
(150 mM, pH 7.4) and rinsed three times with PBS.
After fixation, the cells were permeabilized for 30 min
with saponin (0.2%) and BSA (3%) in PBS, incubated for
2 hrs with filipin at RT (90 μg/ml in PBS), rinsed with
PBS and mounted in Mowiol.
PC12 cell labeling
For immunostaining of PC12 cells with the lysosomal
marker LAMP2, cells were fixed and permeabilized as
described above, incubated for 1 hr at RT with a rabbit
polyclonal antibody against LAMP2 (1:1000) in PBS
containing saponin (0.05%) and BSA (3%) and rinsed
three times with PBS. PC12 cells were subsequently
incubated in the same buffer containing Alexa Fluor
488-conjugated donkey polyclonal antibody against rab-
bit IgGs (1:400) for 2 hrs in the presence of filipin, then
rinsed and mounted in Mowiol.
For Tau immunostaining of differentiated PC12 cells,
cells were seeded as described above for the differentia-
tion assays and maintained for 24 hrs with NGF (5 ng/
ml) in DMEM/glutamine/high glucose supplemented
with 1 mg/ml BSA. Then, the cells were treated for
another 48 hrs with or without U18666A (2 μg/ml) in
the same buffer. Tau immunostaining of PC12 cells was
performed essentially as described in [37]. Briefly, after
treatments, PC12 cells were rinsed with warmed extrac-
tion buffer (EB) containing MgCl2 (1 mM), EGTA (1
mM), GTP (1 mM), glycerol (30%) and PIPES buffer (70
mM), pH 6.9; incubated for 30 seconds with EB contain-
ing saponin (0.2%); and rinsed again with EB. PC12 cells
were then fixed in EB containing paraformaldehyde (2%)
and glutaraldehyde (0.2%) for 1 hr at room temperature.
This procedure was followed by a rinse with PBS and
cell permeabilization in PBS supplemented with Triton
X-100 (0.2%) for 2 min. Cells were blocked by treatment
with PBS containing BSA (4%). PC12 cells were then
incubated with a primary monoclonal antibody against
TAU5 (1:100) or AT8 (1:200) overnight at 4°C. PC12
cells were then rinsed and incubated for 90 min at RT
with donkey anti-mouse Alexa 488 (TAU5) or Alexa
594 (AT8) antibody, rinsed and mounted in Mowiol.
Transfection of PC12 cells with rabs and imaging
PC12 cells were transfected with Lipofectamine-2000
and plasmids containing the cDNA of Rab5-EGFP or
Rab7-EGFP according to the manufacturer’s instruc-
tions. After 24 hrs, PC12 cells were treated for an addi-
tional 24 hrs with or without U18666A (2 μg/ml), fixed
and processed for filipin staining as described above.
PC12 cells were transfected with the Rab7-EGFP plas-
mid and, 24 hrs later, treated with U18666A (2 μg/ml)
for 24 hrs in the presence of NGF (to increase cell
soma). After treatment, PC12 cells were washed three
times with PBS, and the coverslip was inverted in 100 μl
of warmed incubation media in a silicon rubber cham-
ber on a microscope slide. Rab7-labeled endosome
dynamics were imaged in living cells.
For time-lapse visualization of Rab7-positive endo-
somes in PC12 cells, Rab7-labeled endosome dynamics
were imaged in vivo and digitized by capturing one
frame every 0.942 sec for approximately 2 min (a total
of 250 frames) with a FluoView software station. Images
were captured with an Olympus FluoView 1000 with a
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filter-type detector confocal microscope mounted on an
inverted IX81 motorized microscope. Time-lapse experi-
ments were performed with the 488-nm laser line of a
multi-argon laser at 20% transmittance with an UPLS
APO100xO 1.4NA oil immersion objective. Images were
captured with Olympus Software FV10-SW with a pixel
resolution of 512 × 512.
Endocytosis of GM1 and endogenous TrkA in PC12 cells
For endocytosis of GM1 and immunoendocytosis of
TrkA, PC12 cells were seeded to a final confluence of
50%, and U18666A (2 μg/ml) was added after 12 hrs.
After 24 hrs, PC12 cells were serum-starved for 90 min
in 1 mg/ml BSA in DMEM/glutamine/high glucose/
HEPES without phenol red (incubation media) and
washed with cold PBS. To visualize GM1 accumulation
in endosomes, PC12 cells were incubated for 30 min at
37°C with Alexa Fluor 555-conjugated cholera toxin
subunit-B (CT-B) (20 μg/ml), washed, fixed and
mounted in Mowiol. To visualize the internalization of
endogenous TrkA into endosomes, PC12 cells were
incubated with 10 μg/ml rabbit TrkA (Upstate) polyclo-
nal antibody in incubation media for 1 hr at 4°C. Then,
PC12 cells were incubated for an additional hour with a
donkey anti-rabbit Alexa Fluor 488-conjugated antibody
(8 μg/ml), washed, and incubated for 2 hrs at 37°C.
Cells were then washed, fixed and mounted in Mowiol.
Internalization and recycling of TrkA-flag in PC12 cells
PC12 cells were seeded to a final confluence of 50%.
After 12 hrs, U18666A was added (2 μg/ml) for an addi-
tional 24 hrs. Lipofectamine-2000 was then used accord-
ing to the manufacturer’s instructions to transfect PC12
cells with a plasmid expressing TrkA with a Flag epitope
tag at its amino terminus (TrkA-Flag). After transfec-
tion, U18666A (2 μg/ml) was added for an additional 24
hrs. Afterward, PC12 cells were serum-starved for 90
min in incubation media, washed with cold PBS, treated
for 15 min at 37°C with Alexa Fluor 488-labeled mono-
clonal anti-Flag antibody (8.8 μg/ml), washed and incu-
bated for an additional 1 hr and 45 min at 37°C in the
presence of NGF (50 ng/ml). For recycling experiments,
the anti-Flag Alexa Fluor 488 antibody was allowed to
internalize in the presence of NGF for 45 min. Then,
PC12 cells were washed with ice-cold EDTA (1 mM) in
PBS three times for 3 min (to remove the anti-Flag anti-
body, as described by [38]) and incubated with an anti-
Alexa Fluor 488 monoclonal antibody (10 μg/ml) for 60
min at 37°C. Finally, PC12 cells were washed, fixed and
mounted in Mowiol.
Anti-flag labeling
The mouse monoclonal anti-Flag antibody (2.2 mg/ml)
was incubated in 0.1 M bicarbonate buffer, pH 9.0, in
the presence of Alexa Fluor 488 5-TFP (1 mg/ml) for 60
min at room temperature with gentle stirring with a
vortexer. Next, the labeled antibody was purified by gel
filtration (Bio-Gel P30, Bio-Rad) in Bio-Spin columns
(Bio-Rad).
To measure the fluorescence associated with the peri-
nuclear region of PC12 cells, a concentric circle was
drawn using the smallest diameter of the cell with the
ImageJ program (National Institutes of Health, USA).
Inside this circle, another concentric circle, with half the
diameter of the larger circle, was drawn. The fluores-
cence associated with the smallest circle was considered
the perinuclear-associated fluorescence.
To calculate the endosomal volume of TrkA-positive
endosomes, a tridimensional reconstruction using the
ImageJ program was performed for each cell from Z-
Stacks obtained with a confocal microscope. The endo-
somal volume was calculated by multiplying the larger
diameter, the smaller diameter and the thickness of each
endosome.
For transferrin loading of PC12 cells, cells were
serum-starved for 90 min in incubation media and trea-
ted for 2 hrs at 37°C with Alexa Fluor 568-labeled trans-
ferrin (10 μg/ml or 60 μg/ml) in the same culture
medium. Cells were then rinsed with PBS, fixed and
mounted in Mowiol.
Kinetics of NGF-activated signaling pathways in control
and PC12-U18666A cells
PC12 cells at high density (70%) were grown on 3-cm
plates in complete media and treated with U18666A (2
μg/ml) for 24 hrs. PC12 cells were then serum-starved
for 2 hrs in DMEM/glutamine/high glucose-containing
BSA (1 mg/ml) and treated for different durations (0-
360 min) in the same media with NGF (5 ng/ml) in the
presence of U18666A. To stop the treatment, PC12 cells
were rinsed with cold PBS and lysed for 30 min in ice-
cold lysis buffer [HEPES (50 mM), NaCl (150 mM),
EGTA (1 mM), MgCl2 (5 mM), glycerol (10%) and Tri-
ton X-100 (1%)] supplemented with protease and phos-
phatase inhibitor cocktails. The PC12 supernatant was
obtained after centrifugation, and proteins were mea-
sured using the Bio-Rad DC protein assay. Western
blotting was performed with antibodies specific for
phospho- and total Akt, ERK1/2 and PLC. Detection
was performed with HRP-conjugated secondary antibo-
dies and the West Pico ECL kit (Pierce). To measure
ChAT, pAkt and Akt levels in the brain, the medial sep-
tum of WT and NPC1-/- mice was micro-dissected and
homogenized in cold lysis buffer supplemented with
protease and phosphatase inhibitor cocktails. The brain
tissue supernatant was obtained after centrifugation, and
proteins were measured with the Bio-Rad DC protein
assay. Western blotting was performed with specific
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antibodies, and detection was carried out with HRP-con-
jugated secondary antibodies and the West Pico ECL kit
(Pierce).
TrkA immunoprecipitation
PC12 cells seeded in 10-cm plates were treated as
described above for the activation of NGF signaling
pathways. PC12 cells were then washed with ice-cold
PBS and lysed with buffer containing Tris (20 mM) pH
8.0, NaCl (150 mM), Igepal (1%), glycerol (10%) and
EDTA (2 mM) and supplemented with protease and
phosphatase inhibitor cocktails. Immunoprecipitation
was performed as described previously [39].
Microscopy
Optical and fluorescent microscopy were performed
with brain sections and PC12 cells. Most of the digitized
images were obtained with an Olympus BX51 (Tokyo,
Japan) optical microscope (20× objective) equipped with
a CoolSnap-Pro digital camera (Media Cybernetics,
Maryland, USA) and connected to an image analysis sys-
tem based on the Image-Pro Express software, version
5.1.0.12 (Media Cybernetics). The pictures were ana-
lyzed with SigmaScan software (SPSS; Chicago, Illinois,
USA). Panoramic views of the MS were obtained with a
20× objective. Amplified images were taken with a 63×
objective. Image analysis of PC12-related pictures was
performed with the public-domain Image J 1.43
software.
ChAT levels in septal cholinergic neurons were quan-
tified in images digitized by an Olympus IX71 inverted
microscope equipped with a QImaging QICAM Fast
1394 digital camera and connected to an image analysis
system based on the Image-Pro Express software (ver-
sion 6.3.0.531, Media Cybernetics). Images of the septal
areas from three animals per treatment (two coronal
sections per animal) were analyzed. Images were digi-
tally inverted, and the integrated intensity was measured
for each ChAT immunopositive cell using the ImageJ
software. For each treatment, the values of integrated
intensity were averaged and compared with Student’s t-
test over a total of 180 cells per treatment in the case of
ChAT and 54-61 cells in the case of TrkA. The total
intensities of the ChAT and TrkA immunohistochemical
or immunofluorescent levels per cell were standardized
by the total size of the neuron that was quantified.
Confocal images from p75-labeled brain sections were
collected using a Zeiss LSM Pascal 5 [including a triple
laser module (Arg 458/488/514 nm, HeNe 543 nm,
HeNe 633 nm; Carl Zeiss, Thornwood, NY)] connected
to an inverted microscope (Axiovert 2000) with a 63×
objective. Confocal images of ChAT-, NeuroTrace- and
Fluoro-Jade C-labeled brain sections from axotomized
brains were collected with a Olympus FluoView 1000
with a filter-type detector confocal microscope mounted
on an inverted IX81 motorized microscope. Pictures of
the septal areas from three animals per treatment (two
coronal sections per animal) were analyzed to measure
the intensity of ChAT staining and to quantify the num-
ber of NeuroTrace-positive neurons. For ChAT staining,
images were digitally inverted, and the integrated inten-
sity was measured for each ChAT-immunopositive cell
with the ImageJ software. For each treatment, the values
of the integrated intensities were averaged and com-
pared with Student’s t-test over a total of 92 ChAT-
positive cells in the contralateral side of the axotomy
and 40-43 ChAT-positive cells in the ipsilateral side of
the axotomy. The number of neurons positive for Neu-
roTrace was manually counted from the digitized
images. Only the cells that were inside a grid as shown
in Additional file 1: Figure S1 were considered.
Data analysis of brain sections and PC12-related
experiments
Comparisons between the axotomized and unlesioned
sides of the septum were statistically validated by Stu-
dent’s t-test to determine the level of significance (p <
0.05). The analyses were performed using the septum
contralateral to the lesioned side as a control (100%).
Comparisons between control and PC12-U18666A
cells were statistically validated by Student’s t-test (or
two-way ANOVA) to determine the level of significance,
as indicated in the figure legends.
Results
We used two different models to assess whether the
NPC1 deficiency and endosomal abnormalities caused
by cholesterol accumulation in the late endocytic path-
way disrupted NGF signaling. First, we studied NGF sig-
naling in vivo using the septo-hippocampal pathway,
which responds to NGF after axotomy, by stabilizing the
levels of choline acetyl transferase (ChAT) in axoto-
mized cholinergic neurons. In addition, we established a
cell culture model of NPC by treating PC12 cells with
the drug U18666A.
We used axotomy of the septo-hippocampal pathway
with infusion of NGF by osmotic pumps to assess
whether NGF signaling was altered in NPC1-/- mice.
Loss of the cholinergic phenotype in cholinergic neu-
rons after axotomy can be prevented by the intracereb-
roventricular infusion of NGF [40]. NGF receptors
depend on endosomal transport for proper signaling,
and endosomal function is heavily altered by NPC
[6,41]. Cholinergic neurons from the MS of WT and
NPC1-/- mice were visualized by immunohistochemistry
against choline-acetyl transferase (ChAT) and p75.
Although the number of cholinergic neurons in the MS
remained unchanged (Figures 1A and 1B), the
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morphology of MS cholinergic neurons was clearly dis-
torted (Figure 1A). Neurons appeared to be rounder and
hypertrophic (Figure 1C and 1D), with reduced densities
of proximal and distal fibers (Figure 1E). Cholinergic
fibers in the MS were labeled with an antibody against
p75 because this antibody better defines the cholinergic
fibers compared to ChAT staining (Figure 1A and Addi-
tional file 2: Figure S2A). In addition to cholinergic fiber
abnormalities, we also observed a five-fold increase in
axonal spheroid staining for neurofilaments in the MS
(Additional file 2: Figure S2B). Axonal spheroids are
focal axonal swellings filled with organelles and cytoske-
letal proteins and are one of the first neuropathological
hallmarks of axonal disease [42]. These morphological
abnormalities correlate with the fact that NPC1-/- choli-
nergic cells of the MS were loaded with cholesterol
(Additional file 3: Figure S3), confirming that MS choli-
nergic neurons are affected by NPC1 deficiency.
As shown previously in rats and mice [43-45], axot-
omy of the septal cholinergic neurons in WT and
NPC1-/- mice caused an approximately 50% loss of
ChAT-positive neurons (Figure 2A and 2B) and an
approximately 70% reduction of total cholinergic inner-
vation, as shown by acetylcholinesterase (AChE) staining
in the hippocampal side ipsilateral to the brain lesion
(Additional file 4: Figure S4C). In addition, we analyzed
the AChE reduction in specific regions of the hippocam-
pus and observed that there was a greater reduction of
cholinergic axons in NPC1-/- mice compared to WT
mice in the DG and the CA1b region of the hippocam-
pus (Additional file 4: Figure S4E). We also quantified
the total number of neurons in the MS with a general
neuron-specific stain to investigate whether any other
population of neurons in the MS was affected by the
axotomy. The total level of neurons was similar in WT
and NPC1-/- mice, and no staining was evident with
Fluoro-Jade, a histochemical stain for degenerating neu-
rons [46] (Additional file 1: Figure S1).
These observations indicate that although NPC1-/-
cholinergic neurons had morphological abnormalities,
they were not more vulnerable to axotomy than WT
neurons. These results are consistent with our recently
published observations showing a lack of degeneration
of MS cholinergic neurons after axotomy in rats [40].
Although axotomy causes similar cholinergic neuronal
loss in the MS of WT and NPC1-/- mice, we quantified
the intensity of ChAT immunofluorescence from choli-
nergic cells in the contralateral and ipsilateral sides of
the MS 7 days after axotomy. We observed that the cho-
linergic cells of the contralateral side of the axotomy
had similar levels of ChAT staining in NPC1-/- mice and
WT mice; however, the cholinergic cells of the ipsilat-
eral side of the lesion in the MS had increased staining
for ChAT in NPC1-/- mice compared to WT mice
Figure 1 Characterization of NPC1-/- septal cholinergic neurons.
A. Brain sections at the level of the medial septum (MS) from 8-
week-old WT and NPC1-/- mice were stained for ChAT and visualized
with secondary antibodies conjugated to HRP. The insets show a
magnification of the cholinergic cells in the upper panels. WT
cholinergic neurons are smaller and less rounded than NPC1-/-
cholinergic neurons, and there is a reduction in the number of
cholinergic fibers surrounding the labeled NPC1-/- cholinergic cells.
B. The number of ChAT-labeled cholinergic neurons was quantified
in the septal area of WT and NPC1-/- brain sections. Four sections
from six WT and six NPC1-/- age-matched mice were used for
quantification. There are no differences in the number of septal
cholinergic neurons, p = 0.829. C and D. The morphology of septal
cholinergic neurons was evaluated in ChAT-stained brain sections
from WT and NPC1-/- mice. NPC1-/- cells have an increased area and
exhibit a higher ratio between the minor and major axes of
cholinergic neurons, * p < 0.006. A total of 600 cells from six WT
and six NPC1-/- age-matched mice were used for quantification. E.
Quantification of p75-labeled cholinergic fibers in different septal
regions without cholinergic neuronal somas, as shown in the insets
of Additional file 2: Figure 2A, *p < 0.0001.
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Figure 2 In vivo NGF response in WT and NPC1-/- mice. A and B. WT and NPC1-/- mice respond similarly to axotomy of the fimbria-fornix.
Brain sections from 8-week-old axotomized (unilateral fimbria-fornix axotomy) WT and NPC1-/- mice were stained with an antibody against ChAT
(A). Quantification shows an evident and similar reduction in the number of neurons labeled with ChAT (B). The differences between the
phenotypes are not significant, p = 0.755. C. Brain sections from 8-week-old axotomized WT and NPC1-/- mice were immunostained for ChAT,
and the images were acquired by confocal microscopy. In WT mice, axotomized septal neurons (IL, ipsilateral to the axotomy) exhibit lower
levels of ChAT than contralateral neurons (CL). In NPC1-/- mice, ChAT staining in the axotomized septal neurons is similar to that in the
contralateral neurons. D. The quantification of ChAT intensity in septal neurons (90-92 neurons for contralateral side and 40-42 neurons for
ipsilateral) from three WT and three NPC1-/- mice demonstrates a significant reduction in the ChAT levels in WT axotomized neurons, while
NPC1-/- axotomized neurons appear protected, *p < 0.005, unpaired one-way ANOVA. The increased staining of ChAT-labeled cells in C and D is
not due to increased cell size because the total fluorescence or immunostaining intensity of each cell was normalized by cell area. E. Upper
panel: ChAT levels were analyzed by western blot using homogenates of the MS from three 8-week-old WT and three NPC1-/- mice. Bands
corresponding to ChAT from three different WT and NPC1-/- mice are shown. Lower panel: quantification of the western blot indicates that ChAT
levels are significantly higher in NPC1-/- mice than in WT mice. *p < 0.01, unpaired Student’s t-test. n = 3 animals per phenotype. ChAT was
normalized against total Akt. F-H. Increased ChAT staining in response to NGF infusion in NPC1-/- septal cholinergic neurons. Brain
sections from 8-week-old axotomized WT and NPC1-/- mice infused with NGF for one week (F). Black arrows indicate cholinergic neurons with
increased ChAT staining. Quantification shows that NGF protected septal cholinergic neurons equally in WT and NPC1-/- mice (G). Quantification
of ChAT staining in cholinergic cells (as indicated by the arrows in F). AU, arbitrary units. The differences are statistically significant, *p < 0.0001.
Two sections through the medial septum of four WT and four NPC1-/- age-matched mice were used for quantification. A total of approximately
180 cells were considered for each phenotype (H).
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(Figure 2C and 2D). We also observed increased ChAT
levels in MS homogenates from NPC1-/- mice compared
to WT mice (Figure 2E). Because chat is under the con-
trol of NGF signaling, these results suggest an increased
response to endogenous NGF [47,48]. Finally, to deter-
mine whether axotomized MS cholinergic neurons in
NPC1-/- mice respond to NGF in vivo, we infused WT
and NPC1-/- mouse brains with NGF for 7 days starting
after the surgery. Surprisingly, NPC1-/- cholinergic neu-
rons responded similarly to WT neurons in response to
the lesion and NGF treatment, with protection of
approximately 80% of axotomized cholinergic neurons
(Figures 2F and 2G). The reduction of AChE staining in
the whole hippocampus was similar in WT and NPC1-/-
mice (Additional file 4: Figure S4D and F). However,
consistent with the suggestion that NPC-/- cholinergic
neurons have an increased response to NGF, the axoto-
mized cholinergic neurons from NGF-infused NPC1-/-
mice exhibited increased ChAT staining compared to
WT in the contralateral and ipsilateral sides of the
lesions (Figure 2F and 2H). Because we found similar
levels of AChE in the hippocampus of non-axotomized
NPC1-/- mice (Additional file 4: Figure S4A and B), we
hypothesize that the increase in ChAT after NGF infu-
sion was not due to altered anterograde axonal transport
in cholinergic cells from NPC1-/- mice but to an
increased response to exogenous NGF. Altogether, these
results suggest that cholinergic neurons from NPC1-/-
mice are more sensitized to NGF than those from WT
mice.
To further elucidate the mechanism by which NPC1-/-
cholinergic neurons are sensitized to NGF signaling, we
established a cell culture model of NPC by treating
PC12 cells with the drug U18666A. PC12 cells are a
good model in which to study NGF signaling because
they express p75 and TrkA and respond to NGF by dif-
ferentiating into a sympathetic-like neuron [30,31].
Treating PC12 cells with increasing concentrations of
U18666A for 24 hrs resulted in a gradual accumulation
of free cholesterol inside the cells, as measured by filipin
staining. In addition, similarly to other NPC1 cellular
models, PC12 cells treated with U18666A (PC12-
U18666A) exhibited cholesterol and ganglioside GM1
accumulation and increased cell size as a result of cho-
lesterol overload. Similarly to other NPC1 models,
PC12-U18666A exhibited a change in the distribution
pattern of late endosomes, yielding a structure similar to
a ring filled with free cholesterol and with reduced
mobility (Additional file 5: Figure S5, Additional file 6:
Figure S6) [13,16,49-52]. All of these results indicate
that PC12 cells treated with the drug U18666A are a
good model for assessing the different cellular and
molecular consequences of the NPC1 phenotype related
to NGF signaling.
To assess whether the NPC1 phenotype is translated
into morphological alterations in PC12-U18666A cells,
we differentiated PC12-U18666A cells with NGF for two
days. We observed an increased number of differentiated
cells in PC12-U18666A cells compared to controls (Fig-
ures 3A and 3B). In addition, PC12-U18666A cells had
more and longer neurites per cell (Figure 3B). To assess
the effect of U18666A in neurite outgrowth and to pre-
clude the effect of differentiation, we first differentiated
naïve PC12 cells with NGF and then treated the cells
with NGF alone or in the presence of the drug for
another 24 hrs. Under these conditions, we did not
observe a difference in the number of differentiated cells
(cells with a neurite at least twice as long as the dia-
meter of the cell body) or neurites, but neurite length
increased significantly (Figure 3C and 3D). PC12 cells
that were first treated with NGF for 24 hrs and then
treated for an additional 48 hrs with U18666A in the
presence of NGF did not survive (Figure 3E), in contrast
to PC12-U18666A treated for 48 hrs with NGF, indicat-
ing that the increased neurite effect observed in Figures
3C and 3D did not lead to survival but was part of a
degenerative process. To eliminate the possibility that
the effect of U18666A on neurite length was due to the
drug itself and not the NGF response, we differentiated
PC12 cells with NGF for 24 hrs and then treated the
cells with the drug alone or with NGF for another 24
hrs. We observed that PC12 cells treated with the drug
alone retracted their neurites, a change that was evident
when compared to the PC12 cells that were treated with
NGF (Figure 3F). Finally, to assess whether the neurite
growth process was due to IP3K-Akt signaling (see
below), we treated NGF-treated PC12 cells for 24 hrs
with NGF or with NGF plus wortmannin (a specific
inhibitor of IP3K). We observed that PC12 cells treated
for 24 hrs with wortmannin (in the presence of NGF)
retracted their neurites compared to PC12 cells that
were treated only with NGF (Figure 3F). These results
suggested that PC12-U18666A, similar to NPC1-/- choli-
nergic neurons, are sensitized to NGF, leading to
increased neurite length, a process that is related to
degeneration and not survival.
To assess whether the endosomal abnormalities trans-
late into misregulation of receptor signaling, which
could explain increased neurite length, we measured the
activation of different signaling pathways downstream of
TrkA, such as ERK1/2, PI3K/Akt and PLC-g. Although
there were similar basal levels of Akt and PLC-g in
PC12-U18666A and control cells, after 5 min of NGF
treatment, there was an approximately 150% increase in
Akt phosphorylation and a 40% increase in active PLC-g
in PC12-U18666A cells compared to the controls (Fig-
ures 4A, C and 4E). The increase in Akt phosphoryla-
tion lasted for up to 2 hrs after NGF addition, returning
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to basal levels just after 3 hrs (Figures 4A and 4C). This
increased response to NGF was not due to increased
levels of total TrkA or to a slower down-regulation of
the receptor because the total TrkA level was the same
immediately following NGF addition and 2 hrs later
(Figure 4B). In addition, a similar level of TrkA
Figure 3 Increased neurite length in NGF-treated PC12-U18666A compared to controls. A. PC12 cells were treated for 24 hrs with 2 μg/ml of
U18666A and for another 48 hrs with the same dose of the drug in the presence of NGF (5 ng/ml). After the treatments, PC12 cells were fixed and
stained for filipin. B. The number of differentiated cells (cells with a neurite at least twice the diameter of the cell body), the length of the neurites and
the number of neurites per cell were quantified in control and PC12-U18666A cells. A total of 100 cells from three different experiments were
quantified. The differences between treatments are significant, *p < 0.02. C. PC12 cells were treated for 24 hrs with NGF (5 ng/ml) and for an additional
24 hrs with NGF alone (48 hrs NGF) or in the presence of U18666A (2 μg/ml) (48 hrs NGF + 24 hrs U18). D. The number of differentiated cells, the
length of neurites and the number of neurites per cell were quantified in the conditions defined in C. The differences between treatments are
significant, *p < 0.02. E. PC12 cells were treated for 72 hrs with NGF (72 hrs NGF) or 24 hrs with NGF followed by 48 hrs with U18666A (72 hrs NGF +
48 hrs U18). Cells treated with the drug are stained, as shown in the representative images. F. PC12 cells were treated for 48 hrs with NGF (48 hrs NGF)
or 24 hrs with NGF followed by 24 hrs with U18666A in the absence of NGF (24 hrs NGF + 24 hrs U18). PC12 cells treated with the drug in the
absence of NGF retracted neuritis, which is evident compared with cells that were treated with NGF for 48 hrs. G. PC12 cells were treated for 48 hrs
with NGF (48 hrs NGF) or for 24 hrs with NGF followed by 24 hrs with wortmannin (100 nM) in the presence of NGF. PC12 cells treated with
wortmannin retracted neuritis, indicating that neurite elongation is at least partly regulated by IP3K signaling.
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Figure 4 Increased Akt activation in NGF-treated PC12-U18666A and in the medial septum of NPC1-/- mice compared to WT. A. PC12
cells were treated for 24 hrs with 2 μg/ml U18666A and with 5 ng/mL NGF for different durations (0-360 min). After NGF treatment, PC12 cells
were homogenized, and the samples were processed for SDS-PAGE, blotted and immunolabeled for phosphorylated Akt (pAKT), total Akt (AKT),
phosphorylated ERK1/2 (pERK), total ERK1/2 (ERK), phosphorylated PLC-g (pPLC-g) and total PLC-g (PLC-g). B. PC12 cells were treated for 24 hrs
with 2 μg/ml U18666A (U18666A) or not treated (Control) and then were left untreated (T0) or incubated with NGF for 2 hrs (2 h). After
treatment, PC12 cells were homogenized, followed by immunoprecipitation with a polyclonal antibody against Trk (C14, Santa Cruz) and
immunoblotting for total Trk (upper panel, monoclonal B3, Santa Cruz) or with a monoclonal antibody against phosphotyrosine (pTyr). The
graph shows the quantification of total TrkA in control and PC12-U18666A cells at time 0 (T0) or after 2 hrs of NGF treatment (2 h). The levels of
TrkA are equivalent in both experimental groups. C. The graph shows the quantification of pAkt normalized to total Akt ± SEM from three
different experiments. The differences between treatments are significant, *p < 0.001 (two-way ANOVA). D. The graph shows the quantification
of activated ERK1/2 (pERK) normalized to total ERK ± SEM from five different experiments. The differences between treatments are not significant
(two-way ANOVA). E. The graph shows the quantification of activated PLC-g (pPLC-g) normalized against total PLC-g ± SEM from four different
experiments. The differences between treatments are significant, **p < 0.05, two-way ANOVA. F. Levels of phosphorylated Akt (pAKT) and total
Akt (AKT) were analyzed by western blot of homogenates of the MS of three 8-week-old WT and three 8-week-old NPC1-/- mice. Bands
corresponding to pAkt and Akt from three different WT and NPC1-/- mice are shown. G. Quantification of the western blot shown in F indicates
that pAkt levels are significantly higher in NPC1-/- mice than in WT mice, *p < 0.01, unpaired Student’s t-test. n = 3 animals per phenotype. pAkt
levels were normalized against total Akt.
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phosphorylation was observed after 2 hrs of NGF treat-
ment (Figure 4B). These results indicate that PC12-
U18666A cells had increased Akt phosphorylation after
NGF addition, as characterized by the up-regulation of
Akt activity over a longer time, than that observed in
the control cells. NGF also significantly increased PLC-g
activation in PC12-U18666A cells compared to the con-
trols. However, these results were less robust than the
results obtained for Akt. Consistently, when the levels of
pAkt were measured in homogenates of the medial sep-
tum (MS) (where NGF-responsive neurons are located),
we observed increased pAkt levels in the MS of NPC1
-/- mice compared to WT mice (Figure 4F and 4G).
This result suggests that NGF-responsive neurons may
be more sensitive to NGF, particularly Akt signaling,
compared with WT mice or normal conditions (naïve
PC12 cells). Unlike Akt and PLC-g, ERK1/2 activation
was not significantly up-regulated in PC12-U18666A
cells compared to control cells (Figures 4A and 4D).
These results suggest that the up-regulation of the Akt
signaling pathway may be responsible for the increased
neurite length exhibited by PC12 cells treated with
U18666A.
Finally, we investigated in greater detail the endosomal
abnormalities produced by U18666A treatment of PC12
cells and the trafficking properties of the TrkA receptor.
In addition to changes observed in the distribution of
late endosomes (Additional file 5: Figure S5 and Addi-
tional file 6: Figure S6), we also observed changes in the
distributions of other endosomal populations. In PC12-
U18666A cells, the Rab5-EGFP-positive endosomes
(early endosomes) and transferrin-positive endosomes
(recycling endosomes) exhibited perinuclear localization
rather than peripheral localization, as in untreated cells
(Figure 5A and 5B). This change in endosomal distribu-
tion could reflect changes in the Rab-GTPases and
motor activity, as previously suggested by Gruenberg et
al. [15]. To further assess whether these endosomal
abnormalities are translated into changes in the traffick-
ing capabilities of the TrkA receptor, we studied the
internalization and recycling of the TrkA receptor as
previously reported [38,39]. We found that TrkA-posi-
tive endosomes were larger in size in PC12-U18666A
cells than in control cells (Figure 5C and 5D), and
although PC12-U18666A cells and control cells showed
similar levels of internalization, recycling of the TrkA
receptor was reduced in PC12-U18666A compared to
control cells (Figure 5E and 5F). The reduced recycling
of TrkA was not due to missorting of the receptor to
another intracellular route because after 2 hrs of inter-
nalization in the presence of NGF, most TrkA receptors
were located in the recycling pathway and not the
degradative pathway in both PC12-U18666A cells and
control cells (Figure 5G and 5H). These results suggest
that the abnormalities in endosomal dynamics observed
in PC12-U18666A cells and other cellular models may
contribute to the misregulation of receptor signaling in
the endocytic pathway. To assess whether PC12-
U18666A differentiated with NGF showed any sign of a
degenerative process, we stained the cells with the AT8
antibody, which labels hyperphosphorylated tau protein.
Increased phosphorylation of tau, as measured with the
AT8 antibody, has been demonstrated previously by
western blot in the brain of NPC1-/- mice [53]. Differen-
tiated PC12-U18666A cells showed increased AT8
immunostaining that was distributed throughout the
cell, including in neurites (Additional file 7: Figure S7).
Taken together, our results suggest that NPC1-/- choli-
nergic cells are sensitized to NGF compared to WT
neurons, which correlates with the increased NGF
response in PC12-U18666A. In addition, these results
show that NPC1-/-cholinergic neurons, despite obvious
morphological abnormalities, were able to respond to
NGF in vivo.
Discussion
Our study emphasizes the role of anomalous neurotro-
phin signaling in the neuropathology of NPC and is the
first to demonstrate neuropathological changes in the
septal cholinergic system of the basal forebrain in
NPC1-/- mice. Although several kinases are up-regulated
in NPC brains [54-57], to the best of our knowledge,
this is the first time that up-regulation of a kinase, parti-
cularly Akt, has been linked to a specific signaling trans-
duction pathway such as NGF signaling in NPC.
The goal of our research was to investigate whether
NGF signaling is affected in NPC1 disease in two mod-
els known to respond to NGF. Initially, we analyzed
NGF signaling in vivo by infusing the brains of axoto-
mized NPC1-/- and WT mice with NGF. MS cholinergic
neurons from NPC1-/- mice responded to NGF in vivo
and had increased ChAT staining after NGF infusion
compared to WT mice. Although the increased expres-
sion of ChAT was readily evident in NGF-infused mice,
increased ChAT expression was also detected in the
presence of endogenous levels of NGF in the ipsilateral
side of axotomized NPC1-/- mice compared to the WT
mice. In this case, ChAT levels were measured by
immunofluorescence; however, increased ChAT levels
were also evident in non-axotomized NPC1-/- mice
when the ChAT levels in MS homogenates from
NPC1-/- mice were compared to WT mice by western
blotting. We also found an increased amount of phos-
phorylated Akt in the medial septum of non-axotomized
NPC1-/- mice compared to WT mice. These observa-
tions support the regulation of ChAT gene transcription
by TrkA activation, particularly through the Akt signal-
ing pathway, as described previously [47,48]. The
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Figure 5 Transferrin-positive endosome abnormalities and reduced recycling of the TrkA receptor in PC12-U18666A cells. A. PC12 cells
were transfected with a Rab5-EGFP plasmid (which labels early endosomes in green) and after 24 hrs were treated (U18666A) or not treated
(Control) with U18666A (2 μg/ml) for another 24 hrs. To load the cells with transferrin (labeling recycling endosomes in red), PC12 cells were
serum-starved for 1 hr and treated with transferrin Alexa Fluor 555 (2 μg/ml) for 2 hrs at 37°C. Cells were fixed with paraformaldehyde and
visualized with a confocal microscope. Scale bar, 5 μm. B. The fluorescence from Rab5-EGFP (n = 16-24 cells, from two different experiments)
and transferrin (n = 57-60 cells, from two different experiments) associated with the perinuclear region of PC12 cells was measured and plotted.
C, control PC12 cells. U18, PC12 cells treated for 24 hrs with U18666A (2 μg/ml), *p < 0.0001. C. Immunoendocytosis (2 hrs at 37°C) of
endogenous TrkA (TrkA endogenous) and TrkA-Flag in PC12 cells not treated (Control) or treated (U18666A) for two days with the drug (2 μg/
ml). The arrows indicate the presence of larger endosomes in U18666A-treated PC12 cells than in non-treated cells. D. Volume quantification of
TrkA-positive endosomes of PC12 cells non-treated (C) or treated (U18) with U18666A (2 μg/ml). For endogenous TrkA-labeled endosomes (TrkA
endo), a total of 63-69 vesicles were considered (from 6-7 representative cells from two different experiments). *p < 0.0001. For TrkA-Flag-labeled
endosomes, a total of 15-19 endosomes were considered (from 2 representative cells). *p < 0.0003. E. Immunoendocytosis of TrkA-Flag was
allowed to proceed for 2 hrs at 37°C in the presence of NGF (2 hrs inter). The Alexa Fluor 488-conjugated anti-Flag monoclonal antibody was
then washed from PC12 cells by treatment with cooled EDTA. PC12 cells were fixed and mounted. For recycling experiments,
immunoendocytosis of TrkA-Flag was allowed to proceed for 60 min, and the Alexa Fluor 488-conjugated anti-Flag monoclonal antibody was
then washed from PC12 cells by treatment with cooled EDTA and further incubated with an anti-Alexa Fluor 488 antibody for 60 min at 37°C
(60 min recycling), fixed and mounted. F. The fluorescence associated with PC12 cells after the treatments indicated in E was quantified and
plotted. 2 hrs inter, 2 hrs internalization. 60 min rec, 60 min recycling. To measure the fluorescence associated with PC12 cells after 2 hrs of
internalization of the Alexa Fluor 488-conjugated anti-Flag monoclonal antibody, 61-67 cells were considered from two different experiments. To
measure the fluorescence associated with PC12 cells after 60 min recycling, 23-45 cells were considered from two different experiments. *p <
0.0023. G. To visualize the co-localization of TrkA-Flag with transferrin, PC12 cells not treated (control) or treated (U18666A) with the drug were
incubated with the Alexa Fluor 488-conjugated anti-Flag monoclonal antibody and Alexa Fluor 555-conjugated transferrin (60 μg/ml) for 2 hrs in
the presence of NGF and fixed. H. To visualize the co-localization of TrkA-Flag with LAMP2, PC12 cells not treated (control) or treated (U18666A)
with U18666A were incubated with the Alexa Fluor 488-conjugated anti-Flag monoclonal antibody for 2 hrs in the presence of NGF, fixed and
immunostained with a polyclonal antibody against LAMP2 (lysosomal marker).
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increased Akt phosphorylation found in NGF-treated
PC12-U18666A cells (see below) may partly explain the
increased ChAT levels in NPC1-/- MS cholinergic
neurons.
The conserved response to NGF in NPC1-/- mice was
surprising because we found that the morphological
alterations of MS cholinergic neurons in NPC1-/- mice
were similar to those of neurons from different brain
regions, such as brain stem neurons, of patients with
NPC disease [58]. Purkinje cell loss is a prominent fea-
ture of the NPC1-/- mouse model, and some Purkinje
cells exhibit a severely stunted or retracted dendritic
arbor before neuronal death [59]. These observations,
together with our findings in MS cholinergic neurons,
suggest that dendritic alterations precede neuronal loss
as a general feature of neurodegeneration in the NPC
brain. These results also explain the reduced vulnerabil-
ity of cholinergic neurons compared to Purkinje cells
because cholinergic neurons receive additional trophic
support from hippocampal neurons and oligodendro-
cytes [60-63]. Although cholinergic neurons may be
more protected than Purkinje cells temporarily, the
chronic up-regulation of NGF signaling pathways, such
as Akt, may lead to abnormal phosphorylation of cytos-
keletal proteins. Consistent with this idea, several
kinases, including ERK1/2, CDK5, c-Abl, and PI3K, are
up-regulated in the brains of NPC1-/- mice [54-57].
To gain greater insight into the effect of NPC1 inhi-
bition and cholesterol overload in the endocytic path-
way on NGF signaling, we established a cell culture
model of NPC by treating PC12 cells with the drug
U18666A. As expected, PC12-U18666A cells fully reca-
pitulated the key characteristics of the cellular pheno-
type of cells from NPC patients and cellular models of
NPC disease, such as increased cholesterol, endosomal
abnormalities and GM1 accumulation [50,64].
Although U18666A is a pharmacological tool and its
use may induce other cellular changes that are not
related to the down-regulation of NPC1 function (see
review by [31]), we found that, at the cellular level,
PC12-U18666A cells mirrored the phenotype of other
NPC cellular models [64]. One general observation in
PC12-U18666A cells was that there were profound
changes in the distribution of endosomes. These
changes could have been the result of the misregula-
tion of Rab activities. Rab proteins are small mono-
meric GTPases that regulate many steps of membrane
trafficking, including vesicle formation, vesicle move-
ment along actin microfilament and microtubules and
membrane fusion [65]. In cellular models of NPC dis-
ease, cholesterol overload influences the retrieval of
Rab proteins (Rab4, Rab5, Rab9 and Rab7) from differ-
ent endosomal membranes, which leads to the seques-
tration of Rabs in inactive forms [13-15] and disturbs
the movement of vesicles along microtubules by influ-
encing molecular motor activity [15]. Therefore, the
changes in the endosomal distribution in PC12-
U18666A cells may be related to altered transport and
maturation of these endosomes as a result of the mis-
regulation of motor proteins.
PC12-U18666A cells treated for two days with low
concentrations of NGF exhibited greater differentiation
and more and longer neurites than control cells, indicat-
ing that PC12-U18666A cells are more sensitized to
NGF. This result correlated with an up-regulation of
Akt and PLC-g signaling but not ERK1/2 when PC12-
U18666A cells were treated with NGF for short dura-
tions (15 min-6 hrs). Akt and PLC-g signaling regulate
neuronal morphology in different neuronal types,
including PC12 cells, consistent with increased NGF-
induced differentiation in PC12-U18666A cells [66-68].
The differentiation process in PC12 cells is measured by
quantifying cells that possess neurites that are twice the
diameter of the cell body. Therefore, it is difficult to
separate the process of differentiation from the process
of neurite growth. Therefore, we treated PC12 cells with
U18666A then with NGF. Under these conditions, we
observed increased neurite length but not increased dif-
ferentiation. In addition, neurite growth of differentiated
PC12 cells was inhibited by a specific inhibitor of the
IP3K-Akt pathway (wortmannin). Taken together, these
data suggest that the treatment of PC12 cells with
U18666A increases IP3K-Akt signaling in response to
NGF-induced increased neurite growth. Differentiated
PC12 cells die after 48 hrs of U18666A treatment, and
PC12-U18666A cells treated for 48 hrs with NGF show
increased AT8 phosphorylation, suggesting that the
increase in NGF signaling induced by U18666A treat-
ment is related to a pathological process rather than a
survival signal. The increase in Akt signaling in PC12-
U18666A cells treated with NGF correlates with
increased levels of phosphorylated Akt in the MS of
NPC1-/- mice compared to WT mice. Cholinergic neu-
rons located in the MS normally respond to NGF signal-
ing by increasing ChAT synthesis, suggesting that the
inhibition of NPC1 may also cause increased NGF-sig-
naling in vivo.
The AT8 antibody is one of the most widely used
antibodies against phosphorylated tau and recognizes
neurofibrillary lesions in several neurodegenerative dis-
orders [69]. Interestingly, up-regulation of Akt in AD
brains has been correlated with the presence of AT8
immunoreactivity [70]. Taken together, these results
suggest that, rather than inducing survival, the chronic
up-regulation of signaling pathways such as Akt in post-
mitotic neurons may ultimately misregulate other signal-
ing pathways, leading to abnormal phosphorylation of
the cytoskeleton and neuronal degeneration.
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Several lines of evidence suggest that the abnormal
recycling of receptors may play a role in abnormal sig-
naling and trafficking of receptors in NPC. For example,
the impairment of transferrin and lipid recycling has
been observed in cellular NPC models [14], and the
impairment of Rab function has been proposed to cause
normal influx but slower efflux of components in the
endocytic compartment [50,71]. Indeed, consistent with
a receptor recycling problem in NPC cells, we found an
abnormal distribution of early and recycling endosomes,
increased TrkA-positive endosome size and reduced
recycling of the TrkA receptor in PC12-U18666A cells.
Along with the observation of Lee et al. [38] that NGF-
induced long-lasting activation of Akt signaling depends
on TrkA receptor recycling, our results suggest that the
increased Akt activation in both NPC models may be
due, at least in part, to reduced recycling of the TrkA
receptor. This phenomenon could also explain why
TrkB activation is inhibited in striatal neurons derived
from NPC1-/- mice; TrkB has reduced recycling capaci-
ties than TrkA and thus it is affected differently by the
accumulation of cholesterol [12,38]. Or alternatively,
TrkB may be more sensitive than TrkA to changes in
the cholesterol content of the plasma membrane [72].
Both of these scenarios would give rise to different
responses to downstream signaling by TrkA and TrkB
in the context of the NPC phenotype [11].
Conclusions
We have demonstrated for the first time that the endo-
somal alterations caused by NPC result in the up-regu-
lation of a specific signaling pathway. Some of the
neurodegenerative changes observed in NPC may be
due to misregulation of the signaling networks that nor-
mally control proper neuronal physiological function.
Additional material
Additional file 1: Figure S1. In the left upper panel, brain sections from
8-week-old axotomized WT and NPC1-/- mice were double-stained with
antibodies against ChAT (green) and the neuronal marker NeuroTrace
(red). IL, ipsilateral side to the axotomy. CL, contralateral side to the
axotomy. The ipsilateral side exhibits a reduction in the number of ChAT-
positive neurons but no differences in the NeuroTrace staining. In the
left lower panel, similar brain sections were probed for Fluoro-Jade C; no
neurons were positive for this marker of neurodegeneration. Right panel,
Brain sections from three WT and three NPC1-/- mice were used to count
total neurons in the medial septum; a scheme of the grid used for the
quantification of total medial septum neurons is shown in the left panel.
The quantification reveals a similar number of total neurons in both sides
of WT and NPC1-/- mice.
Additional file 2: Figure S2. The MS of NPC1-/- mice exhibits a decrease
in p75-labeled cholinergic fibers and an increase in spheroids. A. Brain
sections from 8-week-old WT and NPC1-/- mice were stained for p75 and
visualized with secondary antibodies conjugated to HRP. p75 was chosen
because it labels cholinergic fibers better than the ChAT cholinergic
marker. Both proteins are frequently used to label cholinergic cells in
mice. The inset shows a magnification of the cholinergic fibers from the
upper panels. In brain sections from NPC1-/- mice, there are fewer fibers
labeled with p75, and the fibers appear disrupted and less defined. The
reduction of p75-labeled cholinergic fibers surrounding cholinergic cells
is also obvious in this preparation. B. Brain sections from 8-week-old WT
and NPC1-/- mice were stained with an antibody against neurofilament.
Arrows indicate axonal spheroids. The quantification indicates that there
are more axonal spheroids in the medial septum of NPC1-/- mice than in
the medial septum of WT mice, *p < 0.0003. Three sections through the
medial septum of four WT and four NPC1-/- age-matched mice were
used for the quantification of axonal spheroids.
Additional file 3: Figure S3. Cholesterol overload in septal cholinergic
neurons of NPC1-/- mice. Brain sections from 8-week-old WT mice, shown
in A, and NPC1-/- mice, shown in B, were double-labeled with a
polyclonal antibody against ChAT (labeling septal cholinergic cells,
shown in green) and filipin (labeling cholesterol, shown in red). The
arrows in B indicate cholinergic neurons that clearly demonstrate an
accumulation of cholesterol in the soma.
Additional file 4: Figure S4. Analysis of AChE staining in the
hippocampus of NPC1-/- WT mice. A and B. Hippocampal sections from
8-week-old WT and NPC1-/- mice were stained for AChE (A). The
comparison between WT and NPC1-/- brains shows no major differences
in the distribution of cholinergic terminals in the hippocampus (B). The
different anatomic areas analyzed in B are indicated as CA1 (divided into
layers a, b and c) and CA3 for the “cornu ammonis” and DG for the
“dentate gyrus”. The intensity of AChE was measured for each
hippocampal region indicated in A and compared between six WT (gray
bars) and six NPC1-/- (black bars) mice. There were no significant
differences in any of the studied regions (p ≥ 0.19). The lower panel
shows the intensity profile of a line traced along the dentate gyrus (also
indicated in A). Differences in cholinergic terminal density are found only
in the outer molecular layer of the DG (arrow), which is decreased in
NPC1-/- mice. C and E. Brain sections from axotomized NPC1-/- mice and
WT mice were stained for AChE (C). The quantification shows a
differential reduction in AChE staining in cholinergic fibers according to
the hippocampal region considered (as shown in A) in WT and NPC1-/-
mice one week after axotomy (E). For quantification, four sections of five
different mice were considered, *p < 0.04. CL, contralateral side to the
axotomy. IL, ipsilateral side to the axotomy. D and F. Brain sections from
axotomized NPC1-/- mice and WT mice were stained for AChE after one
week of axotomy and concomitant NGF infusion (D). The quantification
reveals similar AChE staining in the hippocampus, even after NGF
treatment, in axotomized WT and NPC1-/- mice, p = 0.2 (F). Four sections
through the MS or the hippocampus of four WT and four NPC1-/- age-
matched mice were used for the quantification. CL, contralateral to the
axotomy. IL, ipsilateral to the axotomy. ** The differences are not
significant, P = 0.2.
Additional file 5: Figure S5. PC12-U18666A cells have an NPC-like
phenotype. Accumulation of cholesterol and GM1 ganglioside. A. PC12
cells were not treated (control) or treated with (2 μg/ml) U18666A for 24
hrs and stained with filipin (shown in red) before fixing with
paraformaldehyde. Left panels, The fluorescence intensity profile of the
red line drawn in the control and PC12-U18666A cells is shown. This
result indicates that there is a difference in the distribution of
cholesterol-labeled organelles. B. Quantification of total fluorescence
intensity of filipin staining in control and U18666A-treated (2 μg/ml)
PC12 cells. These results indicate that PC12-U18666A cells exhibit
increased intracellular accumulation of cholesterol. C. Control or U1866A-
treated PC12 cells were incubated with Alexa Fluor 555-conjugated
cholera toxin subunit-B (CT-B) (20 μg/mL) for 30 minutes to label the
accumulation of GM1 gangliosides in endosomes. The images were
acquired under a confocal microscope. Left panel, There is a significant
increase in the accumulation of GM1 in PC12-U18666A cells compared to
control PC12 cells, *p < 0.0001, unpaired Student’s t-test. n = 470-490
cells per treatment from two different experiments. D. PC12 cells were
treated with 2 μg/ml U18666A for 24 hrs before staining with filipin
(shown in red), fixing with paraformaldehyde and immunostaining for
the lysosomal marker LAMP2 (shown in green). LAMP2 immunostaining
indicates changes in the distribution of lysosomes from a perinuclear to
a widespread distribution similar to the cholesterol-labeled organelles
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shown in A. E. The graph indicates an increase in the diameter of PC12-
U18666A cells compared to control PC12 cells, p < 0.0001.
Additional file 6: Figure S6. Rab7-positive endosomes are abnormal in
PC12-U18666A cells. A. PC12 cells were transiently transfected with Rab7-
EGFP (late endosome marker, shown in green) and, after 24 hrs, treated
with 2 μg/ml U18666A (U18666A) for another 24 hrs before filipin
staining (shown in red). The white arrow indicates a giant Rab7
endosome overloaded with cholesterol. It is also evident that the
distribution of Rab7 vesicles (control) changed as a result of treatment
with U18666A. B. PC12 cells were transfected with a Rab7-EGFP plasmid
and treated with NGF for 24 hrs in the presence (U18666A) or absence
(control) of U18666A, and the dynamics of Rab7-positive vesicles were
compared. The movement of Rab7-positive vesicles was studied by
confocal microscopy of living cells with a frequency of 100 frames/min.
The first frames of the sequences for the control and PC12-U18666A cells
are shown as insets in the upper panels. Then, we condensed 150
frames to 1 frame, shown in the upper panel. High levels of fluorescence
in the projections are a consequence of the presence of static particles.
In the lower panel, the same projections are shown but with
segmentation of intensity ranges into a pseudo-colored scale. Sites with
static endosomes are pink or yellow, and sites with more dynamic
changes in intensity are green. Note that green areas are less apparent in
PC12-U18666A cells, indicating that most of the Rab7-positive
endosomes are static. C. Endosomes of five control and five PC12-
U18666A cells were measured and categorized into three size ranges
(smaller than 0.5 μm, between 0.5 and 1 μm and bigger than 1 μm). The
plot shows a histogram of the endosome size distribution in control or
PC12-U18666A cells. The relative abundance (frequency) of smaller
endosomes is significantly decreased in U18666A-treated cells, while
medium-sized endosomes are more abundant. PC12-U18666a cells also
contain enlarged endosomes. The differences between treatments are
significant, *p < 0.05.
Additional file 7: Figure S7. Increased AT8 immunolabeling in
differentiated PC12-U18666A cells compared to controls. A. PC12 cells
were treated for 24 hrs with 2 μg/ml U18666A and for another 48 hrs
with the same dose of the drug in the presence of NGF (5 ng/ml). After
the treatments, PC12 cells were fixed and immunostained with the TAU5
monoclonal antibody, which labels total tau (green), or the AT8
monoclonal antibody against phosphorylated tau (red). PC12-U18666A
cells have increased size and increased immunoreactivity against
phosphorylated tau in the cell body and neurites. B. The intensity of the
immunostaining of PC12 cells labeled with the TAU5 (which labels
nonphosphorylated epitope in Tau) or AT8 antibody was quantified in
the cell bodies of approximately 50 cells. The total fluorescence level of
each cell was divided by the total area of the cell. The experiment was
repeated three times with the same result, and one representative
experiment was quantified. There was no significant difference in the
fluorescence levels of TAU5 immunolabeling in control and PC12-
U18666A cells, p = 0.6245. The differences in fluorescence levels of AT8-
immunolabeling in control and PC12-U18666A cells are significant, *p <
0.005.
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